These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3936789)

  • 1. Short term survival following perfusion with fluosol-DA for cardiopulmonary bypass.
    Rousou JA; Engelman RM; Breyer RH; Allred C; Forouhar F
    Int J Artif Organs; 1985 Sep; 8(5):281-6. PubMed ID: 3936789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
    Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
    J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluosol-DA: an artificial blood for total cardiopulmonary bypass.
    Engelman RM; Rousou JH; Dobbs WA
    Ann Thorac Surg; 1981 Dec; 32(6):528-35. PubMed ID: 7316587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cold protected hearts extract oxygen from Fluosol-DA during cardiopulmonary bypass.
    Gartman DM; McDonagh PF; Geha AS
    Adv Exp Med Biol; 1984; 180():443-50. PubMed ID: 6534118
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Fluosol-DA during open-heart surgery.
    Engelman RM; Dobbs WA; Rousou JH; Anisimowicz L
    Prog Clin Biol Res; 1983; 122():273-82. PubMed ID: 6878370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body oxygenation using intraperitoneal perfusion of fluorocarbons.
    Faithfull NS; Klein J; van der Zee HT; Salt PJ
    Br J Anaesth; 1984 Aug; 56(8):867-72. PubMed ID: 6430312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic, metabolic, and morphological effects of cardiopulmonary bypass with a fluorocarbon priming solution.
    Stone JJ; Piccione W; Berrizbeitia LD; Dance GR; Schoen FJ; Shemin RJ; Cohn LH
    Ann Thorac Surg; 1986 Apr; 41(4):419-24. PubMed ID: 3963919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluosol-DA infusion on pulmonary vascular permeability in the dog lung.
    Hall JE; Ehrhart IC; Hofman WF
    J Trauma; 1986 May; 26(5):432-7. PubMed ID: 3084806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present status of clinical studies of Fluosol-DA (20%) in Japan.
    Mitsuno T; Ohyanagi H
    Int Anesthesiol Clin; 1985; 23(1):169-84. PubMed ID: 3980104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue oxygenation with graded dissolved oxygen delivery during cardiopulmonary bypass.
    Holman WL; Spruell RD; Ferguson ER; Clymer JJ; Vicente WV; Murrah CP; Pacifico AD
    J Thorac Cardiovasc Surg; 1995 Sep; 110(3):774-85. PubMed ID: 7564446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental study on fluorocarbons as blood substitutes.
    Motta G; Ratto GB; De Barbieri A; Tomellini M; Rovatti M; Sacco A; Castagnola M
    Ital J Surg Sci; 1983; 13(2):89-93. PubMed ID: 6629736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal circulation with perfluorochemicals (Fluosol-DA).
    Hoshino S; Iwaya F; Igari T; Kanno M; Honda K
    J Cardiovasc Surg (Torino); 1982; 23(6):463-9. PubMed ID: 7153234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect of fluorocarbon reperfusion on postoperative cardiac dysfunction of transplanted heart.
    Ueda K; Genda T; Hirata I; Shimada M; Shibata T; Ueda T; Omoto R
    J Heart Lung Transplant; 1992; 11(4 Pt 1):646-55. PubMed ID: 1498127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodilution and myocardial oxygen supply. The influence of fluosol-DA.
    Vogel H; Günther H; Harrison DK; Anderer W; Kessler M; Peter K
    Adv Exp Med Biol; 1989; 248():653-61. PubMed ID: 2782181
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental studies on fluosol DA administration in acute pancreatitis.
    Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygenated fluorocarbon perfusion as treatment of acute spinal cord compression injury in dogs.
    Hansebout RR; van der Jagt RH; Sohal SS; Little JR
    J Neurosurg; 1981 Nov; 55(5):725-32. PubMed ID: 7310494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of controlled reperfusion after ischemia. XIX. Reperfusate composition: benefits of blood cardioplegia over fluosol DA cardioplegia during regional reperfusion--importance of including blood components in the initial reperfusate.
    Acar C; Partington MT; Buckberg GD
    J Thorac Cardiovasc Surg; 1991 Feb; 101(2):284-93. PubMed ID: 1992239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal and fetal effects of exchange transfusion with a red blood cell substitute.
    Cefalo RC; Seeds JW; Proctor HJ; Baker VV
    Am J Obstet Gynecol; 1984 Apr; 148(7):859-67. PubMed ID: 6711627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a perfluorochemical emulsion as a blood gas carrier.
    Mitsuno T; Ohyanagi H; Yokoyama K
    Artif Organs; 1984 Feb; 8(1):25-33. PubMed ID: 6422912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.
    Suyama T; Yokoyama K; Naito R
    Prog Clin Biol Res; 1981; 55():609-28. PubMed ID: 7027272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.